In Part 2 of Elizabeth Holmes’ official SEC deposition regarding Theranos, federal investigators press the founder and former CEO on the inner workings of the company’s blood-testing technology. Under questioning, Holmes addresses the reality behind the "miniLab" (TSPU), the company’s reliance on modified third-party commercial analyzers (including Siemens Advia machines), and how few tests were actually validated or running in the clinical lab during the Walgreens rollout. Investigators also examine internal emails with Sunny Balwani, investor demonstrations, and the strategic shift between Theranos's public promises and laboratory realities. Subscribe to Hidden Killers With Tony Brueski for deep dives, trial coverage, and primary-source depositions from the biggest true-crime and corporate fraud cases. Listen To Hidden Killers Podcast ANYWHERE! Listen Here: https://linktr.ee/hiddenkillers Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/ Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.